Clinical Trial Update: Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating rivaroxaban monotherapy after CYP2C19 genotype-guided management in patients with atrial fibrillation and coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Coronary Artery Disease

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: J.P.S Henriques | Conditions: Atrial Fibrillation, Coronary Artery Disease | Phase 4 | Status: UNKNOWN